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Abstract Cystic fibrosis (CF), the most common lethal
genetic disease among Caucasians, is caused by mutations
in cystic fibrosis transmembrane conductance regulator
(CFTR). CFTR’s main role is to transport chloride ions
across epithelial cell membranes. It also regulates many cell
functions. However, the exact role of CFTR in cellular
processes is not yet fully understood. It is recognized that a
key factor in CFTR-related regulation is its phosphorylation
state. The important kinases regulating CFTR are cAMP-
dependent protein kinase A (PKA) and 5′-AMP-activated
protein kinase (AMPK). PKA and AMPK have opposite
effects on CFTR activity despite their highly similar
structures and recognition motifs. Utilizing homology
modeling, in silico mutagenesis and literature mining, we
supplement available information regarding the atomic-
resolution structures of PKA, AMPK and CFTR, and the
complexes CFTR–PKA and CFTR–AMPK. The atomic-
resolution structural predictions reveal an unexpected
availability of CFTR Ser813 for phosphorylation by both
PKA and AMPK. These results indicate the key role of the
structural flexibility of the serine-rich R-domain in CFTR
regulation by phosphorylation.
Keywords CFTR.AMPK.PKA.Interaction.Molecular
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Abbreviations
CF Cystic fibrosis
CFTR Cystic fibrosis transmembrane conductance
regulator
ABC ATP-binding cassette
TMD Transmembrane domain
NBD Nucleotide binding domain
PKA cAMP-dependent protein kinase A
AMPK 5′-AMP-activated protein kinase
RMSD Root mean square deviation
Introduction
Cystic fibrosis (CF) is caused by mutations in cystic
fibrosis transmembrane conductance regulator (CFTR) [1].
The main function of CFTR is its role as a protein kinase-
regulated chloride channel, but it is a multifunctional
protein. CFTR, located in the apical membranes of
secretory epithelial cells, also anchors a dynamic protein
macro complex involved in multiple cell functions [2].
Clinical observations have identified a large spectrum of
phenotypes of CF, even for patients bearing the same
mutation. These observations cannot be solely explained by
mutations in CFTR. Modifier genes and/or epigenetic
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DOI 10.1007/s00894-011-1029-0factors may be potential severity modulating factors.
Studies suggest that dynamic interactions within the CFTR
interactome—important players in the regulation of cell and
epithelial functions—can serve as severity modulation
factors as well [3].
CFTR belongs to the ATP-binding cassette transporter
(ABC) superfamily of proteins. It is a 1480-amino acid
transmembrane protein with a symmetrical structure: a repeat
composedofatransmembraneregion(TMD)andanucleotide
binding domain (NBD) separated by an intrinsically disor-
dered [4, 5] hydrophilic regulatory domain (R domain). The
R domain is a unique feature among ABC transporters. A
molecular model of the CFTR structure model was prepared
by Riordan’sg r o u p[ 6], but it is not complete. During this
study we successfully extended this model.
Several regulatory factors affecting CFTR chloride
channel activity have been reported, but CFTR chloride
channel activity is regulated mostly by protein kinases [7].
The following kinases have been reported to be involved in
this regulation: cAMP-dependent protein kinase A (PKA),
protein kinase C, Ca
2+/calmodulin-dependent kinase,
cGMP-dependent kinase, CK2 protein kinase [8], and 5′-
AMP-activated protein kinase (AMPK) [9]. This list is
likely still incomplete.
The best described is the process of activating CFTR
channels via phosphorylation by PKA in the presence of
ATP. There are 15 serines that need to be mutated into
alanines before CFTR loses its PKA activation sensitivity;
none of these serines alone is necessary or sufficient for full
PKA response [10]. PKA phosphorylation sites are found
primarily in the R region, but are also found within the
NBD1 sequence [11].
Understanding the mechanisms underlying the regulation
of CFTR by PKA also requires an understanding of the
mechanisms underlying the opposite effect of another
kinase, AMPK, which inhibits the PKA-dependent activa-
tion of CFTR and leads to the inhibition of Cl
− secretion in
vitro and in vivo [12].
AMPK forms a heterotrimer consisting of subunits α, β
and γ. Subunits β, γ and the C-terminal domain of subunit
α form the regulatory part of the protein. The N-terminal
catalytic domain of subunit α possesses the kinase
functionality. Catalytic and regulatory parts are connected
with a flexible linker. It has been shown that the AMPK
regulatory part binds to the NBD domains of CFTR [13–
16]. The R-domain sequence carries two sites recognized
by AMPK: “inhibitory” serines S737 and S768; however,
CFTR phosphorylation by AMPK is decreased by only
∼80% when those two serines are replaced by alanines [7].
In order to gain insight into the interaction between
CFTR and its regulatory kinases, the aim of the present
work was to create atomic-resolution models of the
complexes of CFTR with PKA and AMPK.
Our results allowed us to draw conclusions about the
AMPK–CFTR and PKA–CFTR binding interfaces and to
prove at the structural level a hypothesis regarding the
role of the flexibility of the R domain in CFTR
phosphorylation.
Materials and methods
Sequence analysis
The SwissProt/Trembl [17] database was used as the
source of sequences of human 5′-AMP-activated protein
kinase (AMPK) subunits α1 (id: Q13131), β1( i d :
Q9Y478), γ2 (id: Q9UGJ0), human PKA (id: P17612)
and human cystic fibrosis transmembrane conductance
regulator (CFTR) (id: P13569).
Templates for structural modeling were identified as
sequence homologs among the proteins deposited in the
Protein Data Bank [18] using the BLAST algorithm [19]
and the HHPRED program [20]. Pairwise alignments of
sequences of the AMPK subunits with the chosen
templates were prepared with the Needleman–Wunsch
algorithm [21], and are included in the “Electronic
supplementary material.”
Identified AMPK α1 catalytic domain templates fulfilled
the following conditions: (i) the structure has bound ATP/
ADP and a substrate peptide; (ii) the structure is not altered
by interactions; (iii) sequence similarity enables homology
modeling; (iv) the template structure should have the least
number of gaps in the structure.
Using these conditions, the α-catalytic subunit of mouse
cAMP-dependent protein kinase (pdb: 1JBP:E [22]) was
identified as the best template candidate.
For AMPK β1, the structures of the yeast proteins
SPCC1919.03c and SIP2 (pdb ids: 2OOX:B [23]a n d
2QLV:B [24] respectively) were used as templates. The
best templates to model AMPK γ2 were found to be rat 5′-
AMP-activated protein kinase subunit γ-1, yeast hypothetical
proteinC1556.08c,andnuclearproteinSNF4(pdbids:2V8Q:
E, 2OOX:G and 2QLV:C, respectively). In cases where more
than one template was chosen to model a given subunit, the
structures of the templates were aligned using CE [25]a n d
FATCAT [26].
The sequence of the α-catalytic subunit of mouse
cAMP-dependent protein kinase (pdb: 2GU8 [27]) exhib-
its 97.6% identity to the sequence of human PKA in the
covered fragment 15–351.
Modeling tools
Loop modeling Loops were modeled by searching the
PRODAT database with SYBYL 8.0.
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tion using the AMBER7 99 force field [28], Gasteiger–
Hückel charges, a dielectric constant of 80, and simplex
initial optimization followed by Powell minimization
terminated at a gradient change of 0.1 kcal/(mol Å), as
implemented in SYBYL 8.0.
In silico mutagenesis Side chains of mutated residues were
replaced using SYBYL 8.0.
Visualization Figures representing protein structures were
prepared using PyMol [29].
CFTR modeling
To model CFTR fragment 1156–1208, a secondary struc-
ture prediction was obtained using a Jpred [30] server. We
decided to rely on Jpred because other (transmembrane-
oriented) tools predicted that the sixth helix ends at residue
1148, which is not likely. The predicted helical fragment
(CFTR 1156–1180) was modeled using the sixth helix of
the TMD1 domain as a template, and connected with
NBD2 by modeled loop (CFTR 1181–1208).
CFTR fragment 807–817 was remodeled using
peptide bound to the α-catalytic subunit of mouse
cAMP-dependent protein kinase as template substrate.
The template peptide’s residues RRASI were replaced in
silico by the corresponding CFTR residues RRLSQ; the
residues flanking this sequence were removed. Rotamers
of sidechains had to have: (i) minimal structural overlap
with the existing structure; (ii) minimal full atom
RMSD to the old residues. As a next step, the structure
of the prepared pentapeptide was superimposed on the
original CFTR model 810–814 fragment. The residues
807–817 were removed from the R domain, and the
loops CFTR 807–809 and CFTR 815–817 that link the
prepared 810–814 pentapeptide with the R domain were
modeled.
AMPK modeling
Catalytic domain: SWISS-MODEL was used to model
AMPK α11 –274. The modeling of fragments 289–293 and
302–307 using 1JBP:E as a template and linking all
fragments with loops was carried out in SYBYL.
Regulatory part: SWISS-MODEL [31] was used to
model the C-terminal regulatory domain of AMPK α1,
while SYBYL 8.0 was used to model subunits β1 and γ2.
Two AMPK α1 models with two templates were prepared:
(i) AMPK α1 358–478, using carbon catabolite derepress-
ing protein kinase (pdb: 2QLV:A); (ii) AMPKα1 398–550,
using rat 5′-AMP-activated protein kinase subunit α1 (pdb:
2V8Q:A). Overlapping fragments were structurally aligned
(RMSD 3.06Å) then removed. Models were merged, with
the missing fragment 469–471 modeled as a loop.
There are more gaps in the C-terminal part of the
alignment of AMPK β1 fragment 73–270 with the SIP2
protein β subunit (pdb: 2QLV:B) than in the corresponding
part of the alignment with protein SPCC1919.03c (pdb:
2OOX:B). In the modeling of AMPK β17 3 –157, 2QLV:B
was used as a template; in the modeling of fragment 167–
270, 2OOX:B was used. The models of fragments 73–157
and 167–270 were then structurally aligned with
structure 2QLV:B to obtain their position in the AMPK
trimer (as we used 2QLV:A and C to model other subunits
of the trimer). The missing linker AMPK β1 158–166 was
modeled as a loop.
AMPK γ2 was modeled using nuclear protein SNF4
(pdb: 2QLV:C) as template.
Human PKA modeling
The structure of the mouse PKA catalytic [27] subunit was
used as the template. Eight residues differentiating mouse
PKA from human PKA (T19, S21, Q26, D31, S52, A111,
E163, and T335) were replaced in silico in SYBYL 8.0
with the corresponding human PKA residues S, A, H, E, T,
P, Q, and S, respectively. The structure obtained was
subjected to energy minimization.
Modeling of the CFTR–AMPK complex
The interface region of the regulatory domain CFTR was
defined on the basis of experimentally determined interac-
tion sites described in the literature. The surface and
structure of the interface region was visually scanned for
spacial and hydrophobic complementarity. The identified
area was used to manually construct the complex subjected
to minimization. The catalytic domain was docked to the
CFTR R domain using the previously docked PKA
structure as a template. Complex analysis was performed
using the Solvent Accessible Surface calculator of Michel
Sanner’s Molecular Surface algorithm [32] and the Protein
Interactions Calculator [33]
Results
AMPK model extension
A database search revealed that the available AMPK model
[34] could be extended. Most of the potential templates are
fragmentary and contain different fragments that are
homologous to AMPK. The protein of the sequence most
similar to the catalytic domain of AMPK α1—protein
kinase Chk2—is crystallized as a homodimer, with inhib-
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involved in the formation of the interface [35]. This
dimerization-enabling feature, specific to Chk2, disquali-
fied its structure. The 1JBP:E structure we used has a
RMSD from the Chk2 structure (with T-loop excluded) of
below 2Å.
When modeling the regulatory part, the 2V8Q structure
—which was the most sequentially similar—seemed to be
the best template for trimer modeling. However, the 2V8Q:
E chain was truncated prior to crystallization, resulting in
the deformation of the 190–198 fragment. The 2V8Q
structure was excluded from further modeling of the
regulatory part of AMPK. Structural alignments demon-
strated that the structures 2QLV and 2OOX are almost
identical to 2V8Q (their similarities in terms of the RMSDs
of the protein backbone atom positions are presented in
Table 1 in the “Electronic supplementary material”).
For structure-based interaction predictions, it is of the
upmost importance to use continuous structural models of
the proteins involved, as any discontinuity may contain
potential obstacles or introduce clues for complex forma-
tion. All of our models were extended to meet the
continuity criterion in the interface areas. The range of
extension of the AMPK model is presented in Fig. 1.
CFTR–PKA catalytic domain interaction
Ten residues of CFTR are known to be phosphorylated by
protein kinase A (PKA). However, even mutations of all ten
of these residues do not prevent the activation of CFTR by
PKA [36]. In our model, S813—which is known to have
the strongest activating effect among all serines phosphor-
ylated in CFTR—is the most exposed. We were aware that
the R domain is highly unstable, and that the conformation
under study was just one of many possible. We confirmed
that this conformation allowed the binding of PKA to S813.
After docking human PKA to CFTR, we observed that the
following H-bonds, responsible for substrate peptide rec-
ognition, formed between the recognized pentapeptide of
CFTR (810–814) and both PKA and PKA-bound ADP:
CFTR Arg810–ADP; CFTR Arg810–PKA Tyr331; CFTR
Arg811–PKA Lys169, Glu171; CFTR Ser813–PKA
Lys169; CFTR Glu814–PKA Leu199. These bonds are
presented in Fig. 2a. Lys169 is a residue in the active site
associated with the kinase activity of PKA. The surface
position of S813, on flexible linkers, agrees with data
showing an immediate CFTR response to PKA activation.
S813 is accessible, and its environment allows the rapid
binding of PKA. The overall structure of the CFTR–PKA
complex is presented in Fig. 3a.
CFTR–AMPK catalytic domain complex formation
Riordan’sd en o v om o d e l i n g[ 4] of the R domain provides
many clusters with different conformations. The conforma-
tion presented in the template model used is considered to be
one of many that occur naturally in a cell. The R domain is
connected to other domains via linkers: 658–679 and 843–
847. NMR experiments have shown that the flexibilities of
some R-domain fragments decrease after NBD1 binding [5].
In the conformation used, these parts are internally stabilized,
so they are not predicted to interact directly with NBD1.
There is experimental evidence showing large movements of
the R domain vs. the NBDs and TMDs [37]. As the relative
position of the R domain with respect to channel-forming
domains has not been specified, we treated the linkers as
Fig. 1 In-scale visualization of the AMPK modeling effort. Horizon-
tal boxes depict modeled fragments. Horizontal lines depict fragments
of unknown homologs with known structures, probably unstructured
fragments. Lighter box lines depict fragments of the AMPK model
created in this work; darker lines depict fragments that were
previously modeled. Green fill depicts the predicted interface of
AMPK with CFTR. Grayscaling depicts differences in sequence
between isoforms that interact and do not interact with CFTR
(position-specific score of Needleman–Wunsch alignment of AMPK
α1 vs. AMPK α2 and AMPK γ2 vs. γ1). Black triangles depict gaps:
those pointing up depict gaps in the presented isoform; those pointing
down depict gaps in isoforms that do not interact with CFTR. Shorter
and darker lines depict different residues. Numbers below the lines
describe the range of the model: the pdb id of the template structure
used to model these fragments is shown in gray
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during the docking of the catalytic domains of AMPK α1
and PKA. The R domain extracted from the whole CFTR
model was scanned for the AMPK recognition motif. Two
serines—S737 and S768—were identified. Experimental
evidence of the inhibitory role of AMPK after the phosphor-
ylation of S737 and S768 was provided in previous research
[37–39]. However, experiments [7] have shown an 80%
decrease in AMPK phosphorylation for the CFTR double
mutant S737A-S768A. We decided to use relaxed AMPK
recognized motif, RRXS/TY, to identify other potential target
serines. S813 was identified. We decided to use PKA
previously bound to S813 as a template for AMPK α1
catalytic domain docking. After preparing the R domain–
AMPK catalytic domain complex, the R domain was re-
attached to CFTR.
The R domain with the docked AMPK α1 catalytic
subunit was minimized. The bonds required for substrate
peptide binding by protein kinase [22] were satisfied.
In our model, we observed the following H-bonds
responsible for substrate peptide recognition between the
recognized pentapeptide of CFTR (810–814) and AMPK,
and between ADP and AMPK: CFTR Arg810–ADP; CFTR
Arg811–AMPK Glu145, Tyr181; CFTR Ser813–AMPK
Lys142, Ser178; CFTR Gln814–AMPK Gly177. These
bonds are presented in Fig. 2b. Lys142 is a residue in the
active site associated with the kinase activity of AMPK.
The overall structure of CFTR in complex with the AMPK
catalytic domain is presented in Fig. 3b.
Comparison of the CFTR–AMPK catalytic domain
and CFTR–PKA complexes
Our analysis revealed high probabilities of both complexes.
The interface areas of both complexes measured with
MSMS [32] differed slightly: 2548 Å
2 for CFTR–PKA
compared to 2149 Å
2 for CFTR-AMPK, which suggests
that the PKA–CFTR complex is more stable. However,
both interface areas are typical of heterodimers. More
detailed analysis with PIC [33] showed that although the
AMPK–CFTR interface has only six hydrophobic inter-
actions (in contrast to the nine present at the PKA–CFTR
interface), and it does not form (main chain)–(main chain)
hydrophobic bonds (in contrast to the three bonds formed in
the PKA–CFTR case), its higher number of (main chain)–
(side chain) hydrogen bonds (30 compared to 22) and (side
chain)–(side chain) hydrogen bonds (29 compared to 20)
suggest that both complexes have similar stabilities.
Fig. 2 Interactions of CFTR
pentapeptide 810–814 with
PKA (left) and AMPK (right).
Kinase structures are simplified,
and only residues that form
H-bonds with the pentapeptide
are drawn in detail (yellow
dashed lines). CFTR S813 and
the lysines at the active site
of the kinases are labeled
Fig. 3 Overall structures of the
CFTR–PKA catalytic domain
(left) and the CFTR–AMPK
(right) complexes. Kinases and
CFTR are represented in car-
toon form, while the CFTR
pentapeptide 810–814 is pre-
sented in both pictures in stick
form
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Experimental data for the CFTR–AMPK complex indicate
that (i) the CFTR region 1420–1457 interacts with the 407–
550 region of AMPK α1[ 16], and (ii) the R domain is
phosphorylated by the catalytic domain of AMPK α1[ 12].
Prepared models of AMPK and CFTR lack unstructured
tails: the final complex was defined as exposing terminal
residues of the truncated subunits to the solvent in a way
that enables chain extension. The AMPK regulatory domain
was manually docked to CFTR in the experimentally
confirmed interface area in a manner that conforms with
established restrictions.
The CFTR interface region consists of two parts:
fragment 1420–1428 is part of the NBD, while 1429–
1450 is an unstructured CFTR tail. In our work, we
modeled the interaction with a structured part (1420–
1428), ensuring that the model provides the space
required for the C-terminal tail. The complex was
minimized. Interfaces did not introduce any energetically
unfavorable conformations for any of the proteins; nor
were any of the predicted H-bonds broken due to an
unfavorable environment.
The structure of the CFTR–AMPK regulatory domain
complex is shown in Fig. 4. In the interface created, 52 and
49 residues are involved on the CFTR and AMPK sides
respectively, with a total area of 1856 Å
2. This is an
average surface area for a nonobligatory complex interface.
As further support for our model, we used information on
mutations disrupting the interaction between AMPK α1
and CFTR [16].
Discussion
Our models show that two counteracting kinases, PKA and
AMPK, can phosphorylate CFTR S813, suggesting that the
different effects of AMPK and PKA on CFTR Cl
− channel
activity result from interactions with other proteins and/or
S813 availability.
AMPK binding to CFTR
Our model shows that AMPK regulatory binding to CFTR
is not required for CFTR phosphorylation. However, the R
domain undergoes constant structural changes, hampering
the formation of an appropriate interface. Furthermore, the
R domain has only two phospho sites in the precise AMPK-
recognition motif (S737 and S768), which are inaccessible
in the conformation used. The binding of AMPK to CFTR
with the regulatory domain may provide the time required
for the R domain to change conformation, thus allowing
access to the “inhibitory” serines.
S813 phosphorylation by PKA and AMPK
The complexes of CFTR with the catalytic subunit of PKA
and the catalytic domain of AMPK α1 are bound at the
S813 site within the R domain.
Our model of S813 binding by PKA is consistent with
experimental evidence: the active-site lysine (K169) is able
to react with S813 and bind adenosine phosphate. AMPK
bound to S813 in the same conformation as PKA, and did
not differ from it in terms of the H-bonds formed and
interface stability. This result suggests that AMPK may
phosphorylate S813. This shows that, at the molecular
level, it is possible that 20% of the currently unexplained
phosphorylation signal observed in the CFTR double
mutant S737A-S768A incubated with AMPK may come
from “activator” serines such as S813.
Role of CFTR R-domain flexibility in phosphorylation
CFTR activity depends on R-domain phosphorylation
[10, 40]. In the process of CFTR regulation, the R domain
acts as an inhibitor that needs to be phosphorylated to
enable CFTR channel activity [41]. Based on the results of
Fig. 4 Overall structure of the CFTR–AMPK regulatory domain
complex. The main chains of the proteins are colored by chain, with
the R domain highlighted in a lighter green color compared to the rest
of the CFTR protein. Atoms from S737, S768 and S813 in the R
domain are presented as red spheres. CFTR pentapeptide 810–814 is
represented in stick form (except for S813, which is presented in
sphere form)
88 J Mol Model (2012) 18:83–90NMR experiments, Baker et al. described the R domain as
“sampling multiple, heterogeneous conformations, […]
with rapid interconversion between conformers [5].” In
our work, we decided to use one conformation among the
many derived by Riordan et al. by de novo modeling [4].
In our model, the R domain’s structure prohibits the
phosphorylation of the PKA and PKC phospho sites S686,
S712, S768, and S790, which are known to be phosphor-
ylated in vitro under controlled conditions. The latest
experimental results show that the “inhibitory” serines
S737 and S768 introduce an insensitive CFTR mutant into
PKA (in which 15 potential phosphoserines are mutated to
alanines) and restore PKA sensitivity [10]. Considering
the diminishing differences between “activating” and
“inhibiting” serines as well as “serines phosphorylated
by activating and inhibiting kinases,” further structural
analyses of the R domain and the nature of its interaction
with suitable kinases appear to be crucial elements for
elucidating CFTR regulation.
Our results present a molecular explanation for the
phenomenon of the dependence of CFTR phosphoryla-
tion on the flexibility of the R domain. A new question
can thus be formulated: what are the factors that
influence the structural state of the R domain prior to
phosphorylation?
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
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